Drug Manufacturing and Access to Medicine in Nepal – A Literature Review of Challenges and Proposed Remediation

H. Bhatt, K. Santosh, P. Thapa
{"title":"Drug Manufacturing and Access to Medicine in Nepal – A Literature Review of Challenges and Proposed Remediation","authors":"H. Bhatt, K. Santosh, P. Thapa","doi":"10.3329/dujps.v20i3.59802","DOIUrl":null,"url":null,"abstract":"In recent years considerable attention has been paid to the issue of access to medicine. Access to medicine cannot depend on the decision of private industries only but also on government policies and strategies. According to National Health Policy2019, it is the right of all citizens to have basic health care service including access to safe, efficacious and quality medicine. Nepal is a landlocked country in South Asia. Nepal is a diverse country with a varied culture, language, and biodiversity, but generally affected by the common disease (e.g. tuberculosis, COPD, diarrhoeal disease, diabetes and malaria). There are 65 plus private pharmaceutical industries in operation in Nepal and approximately 60% of drugs are imported from India and third-world countries. The only government owned pharmaceutical industry is ‘Nepal Aushadhi Limited’ which is not fully operational in manufacturing essential medicine. Private manufacturers focus mainly on brand competition for private consumption but not in essential medicines. Some essential medicines are totally imported from India and other countries (e.g. insulin). The Nepal government has Free Drug List (FDL) consisting 70 medicines that should be provided free to the all patients but these are not accessible to all citizen of rural areas due to poor logistic management, supply chain and transportation facilities. Quality and adequacy of health services and medicines are the main problem in rural areas. This article mainly focuses on challenges of drug manufacturing and access to safe, efficacious and quality medicines in Nepal. It also emphasizes on strategies and policies being implemented to solve these problems. It is obvious that solving the challenges to provide safe, efficacious and quality medicine is collective responsibility of government of Nepal, private manufacturing industries, regulatory bodies, health professional, the patient and NGO, INGOs working on healthcare system of Nepal.\nDhaka Univ. J. Pharm. Sci. 20(3): 373-379, 2022 (June) Centennial Special Issue","PeriodicalId":11304,"journal":{"name":"Dhaka University Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dhaka University Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/dujps.v20i3.59802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

In recent years considerable attention has been paid to the issue of access to medicine. Access to medicine cannot depend on the decision of private industries only but also on government policies and strategies. According to National Health Policy2019, it is the right of all citizens to have basic health care service including access to safe, efficacious and quality medicine. Nepal is a landlocked country in South Asia. Nepal is a diverse country with a varied culture, language, and biodiversity, but generally affected by the common disease (e.g. tuberculosis, COPD, diarrhoeal disease, diabetes and malaria). There are 65 plus private pharmaceutical industries in operation in Nepal and approximately 60% of drugs are imported from India and third-world countries. The only government owned pharmaceutical industry is ‘Nepal Aushadhi Limited’ which is not fully operational in manufacturing essential medicine. Private manufacturers focus mainly on brand competition for private consumption but not in essential medicines. Some essential medicines are totally imported from India and other countries (e.g. insulin). The Nepal government has Free Drug List (FDL) consisting 70 medicines that should be provided free to the all patients but these are not accessible to all citizen of rural areas due to poor logistic management, supply chain and transportation facilities. Quality and adequacy of health services and medicines are the main problem in rural areas. This article mainly focuses on challenges of drug manufacturing and access to safe, efficacious and quality medicines in Nepal. It also emphasizes on strategies and policies being implemented to solve these problems. It is obvious that solving the challenges to provide safe, efficacious and quality medicine is collective responsibility of government of Nepal, private manufacturing industries, regulatory bodies, health professional, the patient and NGO, INGOs working on healthcare system of Nepal. Dhaka Univ. J. Pharm. Sci. 20(3): 373-379, 2022 (June) Centennial Special Issue
尼泊尔的药品生产和药品获取——挑战和建议补救的文献综述
近年来,人们对获得药品的问题给予了相当大的关注。获得药品不能仅仅取决于私营企业的决定,还取决于政府的政策和战略。根据《2019年国家卫生政策》,所有公民都有权获得基本卫生保健服务,包括获得安全、有效和优质的药品。尼泊尔是南亚的一个内陆国家。尼泊尔是一个多元化的国家,拥有多种文化、语言和生物多样性,但普遍受到常见疾病(如结核病、慢性阻塞性肺病、腹泻病、糖尿病和疟疾)的影响。尼泊尔有65多家私营制药业,大约60%的药品是从印度和第三世界国家进口的。唯一一家政府拥有的制药业是“尼泊尔奥沙迪有限公司”,该公司在生产基本药物方面没有全面运作。私营制造商主要关注私人消费的品牌竞争,而不是基本药物。一些基本药物完全从印度和其他国家进口(如胰岛素)。尼泊尔政府有免费药物清单(FDL),其中包括70种药物,应该免费提供给所有患者,但由于物流管理、供应链和运输设施不佳,并非所有农村地区的公民都能获得这些药物。保健服务和药品的质量和充足性是农村地区的主要问题。本文主要关注尼泊尔药品生产和获得安全、有效和优质药品的挑战。它还强调为解决这些问题而实施的战略和政策。很明显,解决提供安全、有效和优质药品的挑战是尼泊尔政府、私营制造业、监管机构、卫生专业人员、患者和非政府组织(NGO)的集体责任。达卡大学药学院。科学通报,20(3):373-379,2022(6)百年特刊
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信